ClinicalTrials.gg
RecruitingNCT06381531TRACEUpdated Apr 11, 2025

Tracing Brain Tumors Through Deep Time

An observational study in Brain Tumor and Oncology, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Tata Memorial Centre · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
10,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Brain Neoplasms with a site in India — 9 open to participants now, 10 under way, 3 of them phase 3. Brain Neoplasms · India.

Planned enrollment
Largest of 13
10,000 · median 1,372
Started
2025
with 3 others
Observational
13 of 24
4 open now
Registered
14th of 24
by date
Lead sponsor
7 of 24
Tata Memorial Centre

Among the 24 studies in Brain Neoplasms with a site in India, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, and was the 14th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

9 of the 24 studies in Brain Neoplasms with a site in India are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Brain Neoplasms with a site in India, or all of them as a file.
02

Study summary

Brain tumors involve different age groups with a wide range of tumor types involving different anatomical compartments of the brain. The evolution of the brain in vertebrates, including the most recent homo species (including humans), has occurred through increasing structural complexity in more evolved species. In the retrospective study, we will investigate the location of the tumors and different structural aspects of skull anatomy in patients with brain tumors. The information will be compared with the anatomical evolution of the brain and skull in vertebrates to look for possible associations, which can provide insights into evolutionary biology.

Read the detailed description

Patients (pediatric and adults) with a diagnosis (radiological/ histopathological) of primary brain tumors registered in the neuro-oncology disease management group between January 2005 and December 2023 will be screened. Approximately 500-600 patients are expected to be eligible per year with imaging data (approximately 500 patients are treated annually with radiation in our center with available CT data for radiation planning, and another 100-200 patients having pre-operative or post-operative scans). For the above-mentioned time period, data is expected to be available from approximately 10,000 patients, which will be the upper limit of sample size for the current study.

The area of the primary tumor (or cavity and residual tumor indicating original location for post-operative data) will be segmented on CT and /or MRI as available. The peritumoral edema will be excluded from the segmented region. The segmentation will be done manually in an initial cohort of approximately 200-500 patients. Subsequently, a machine learning algorithm like a 3D U-net or deep learning-based technique will be trained on the initial data (and validated on the next 100-200 patients to assess algorithm accuracy and robustness) for rapid implementation and segmentation of the large data set. Once brain tumor regions are identified across the entire population, density maps will be generated to reciprocate the location of tumors on a quantitative scale as per age of the patient during diagnosis (age in years as continuous data and categorical data, i.e., age groups, e.g., infants, children, teens, adolescents. adults, and elderly). The generated density maps will be compared with regions of vertebrate brain regions (with openly available literature) across species with regards to the geological scale/ deep time units, e.g., in units of 10-50 million years. Similarly, the skull bony anatomy will be extracted from CT and/ or MRI data (applying techniques like window intensity thresholds without the need for segmentation). Patients with major defects in the calvarial skull from increased intracranial pressure or surgical interventions will be excluded from the analysis of calvarial anthropometry (however, it will be available for skull base anatomy assessment). The organizational patterns will be analyzed using machine learning models and other statistical models like Bayesian statistics and compared with other publicly available normal human populations without brain tumors (adjusting for age, race as applicable), fossil data of vertebrates/ hominids, non-human primates for link recognition. The density maps and anthropometric data will be compared within the entire cohort of patients with brain tumors (from the study) stratified by factors like age (as mentioned earlier), tumor location (e.g., supratentorial vs. infratentorial), tumor grade (benign vs. low grade vs high grade). The statistical analysis for density maps and anthropometry will be done by sharing anonymized data with collaborators with expertise in similar research from the Indian Statistical Institute (Geological Studies Unit and Interdisciplinary Statistical Research Unit).

03

Conditions studied

  • Brain Tumor
  • Oncology

Keywords

  • CNS tumor
  • Brain tumor
  • Evolution
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diagnosis of primary brain tumors will be screened for the study. Approximately 500-600 patients are treated annually with radiation in our center with available CT data for radiation planning, and another 100-200 patients having pre-operative or post-operative scans. For the above-mentioned time period, data is expected to be available from approximately 10,000 patients, which will be the upper limit of sample size for the current study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients diagnosed with primary brain tumors with available pre/ post-operative or pre-radiation brain images with computed tomography (CT) or magnetic resonance imaging (MRI)

Exclusion criteria

Exclusion Criteria:

  • CT/ MRI is not available before cranial radiotherapy
  • Artifacts causing distortion of skull (bony) anatomy
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testImaging with CT and MRI

    Quantitative and anthropometric analysis of brain and skull strutcure of imaging (CT/ MRI) undertaken as part of diagnosis or treatment for patients with brain tumor

06

What researchers measure

Primary outcomes

  1. Age-based density maps of brain tumor location

    Tumor location for different age groups will be analyzed using proportions (percentage of tumor area in normal brain).

    Time frame: 36 months

Secondary outcomes

  1. Anthropometric analysis of skulls

    Cranial index (maximum cranial width/ maximum cranial length x100) will be analyzed using descriptive statistics (mean, median, range, standard deviation).

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 24, 2024
StartActual
Jan 10, 2025
Primary completionEst.
Jun 10, 2027
CompletionEst.
Jun 10, 2027
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06381531
Lead sponsor
Tata Memorial Centre
Collaborators
Indian Statistical Institute, Kolkata
Responsible party
Dr Archya Dasgupta (Assistant Professor, Radiation Oncology, Tata Memorial Centre) — Principal investigator
First posted
Apr 24, 2024
Start date
Jan 10, 2025
Primary completion
Jun 10, 2027 (estimated)
Completion
Jun 10, 2027 (estimated)
Last update
Apr 11, 2025

Study contacts

ARCHYA DASGUPTA, MD
Contact
archya1010@gmail.com
91-22-24177000 ext. 6861
ARCHYA DASGUPTA, MD
principal investigator · Tata Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion